<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2020-13-3-61-68</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-487</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНО-ЛАБОРАТОРНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL AND LABORATORY STUDIES</subject></subj-group></article-categories><title-group><article-title>Влияние кортикостероидной терапии на процесс рубцевания бактериальной язвы роговицы</article-title><trans-title-group xml:lang="en"><trans-title>The  impact of corticosteroid therapy on the bacterial corneal ulcer  healing process</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нероев</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Neroev</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Владимирович Нероев — академик РАН, доктор медицинских наук, профессор, директор.</p><p>Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Vladimir V. Neroev — Academician of the Russian Academy of Sciences, Dr. of Med.  Sci., professor, director.</p><p>14/19, Sadovaya-Chernogryazskaya st., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яни</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yani</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Владимировна Яни — кандидат медицинских наук, руководитель отдела инфекционных и аллергических заболеваний глаз.</p><p>Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Elena V. Yani — Cand. of Med. Sci., head of department of infectious and allergic eye diseases.</p><p>14/19, Sadovaya-Chernogryazskaya st., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хорошилова-Маслова</surname><given-names>И. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Khoroshilova-Maslova</surname><given-names>I. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Инна Петровна Хорошилова-Маслова — доктор медицинских наук, профессор, руководитель отдела патологической анатомии и гистологии.</p><p>Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Inna P. Khoroshilova-Maslova  — Dr.  of Med.  Sci.,  professor, head  of department of pathological anatomy and histology.</p><p>14/19, Sadovaya-Chernogryazskaya st., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голикова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Golikova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виктория Алексеевна Голикова — аспирант отдела инфекционных и аллергических заболеваний глаз.</p><p>Ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Viktorija A. Golikova — PhD student, department of infectious and allergic eye diseases.</p><p>14/19, Sadovaya-Chernogryazskaya st., Moscow, 105062</p></bio><email xlink:type="simple">viktorydeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>15</day><month>09</month><year>2020</year></pub-date><volume>13</volume><issue>3</issue><fpage>61</fpage><lpage>68</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нероев В.В., Яни Е.В., Хорошилова-Маслова И.П., Голикова В.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Нероев В.В., Яни Е.В., Хорошилова-Маслова И.П., Голикова В.А.</copyright-holder><copyright-holder xml:lang="en">Neroev V.V., Yani E.V., Khoroshilova-Maslova I.P., Golikova V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/487">https://roj.igb.ru/jour/article/view/487</self-uri><abstract><p>Цель работы — провести клинико-морфологическое исследование роли кортикостероидов в заживлении язвенного дефекта на экспериментальной модели бактериальной язвы роговицы.</p><sec><title>Материал и методы</title><p>Материал и методы. Кролики с бактериальной язвой роговицы были разделены на 4 группы по 10 особей (по 10 глаз). В 1-й группе проводилось местное антибактериальное лечение. Во 2-й и 3-й группе к антибактериальному лечению добавлены инъекции раствора дексаметазона 0,1 % 0,2–0,3 мл 1 раз в сутки (парабульбарно или в холку соответственно). В 4-й (контрольной) группе после моделирования язвы роговицы проводили клиническое наблюдение  и изучение изменений без лечения. Структурные изменения тканей глаз оценивали путем патогистологического исследования с помощью микроскопической системы Leica при увеличении 100–600.</p></sec><sec><title>Результаты</title><p>Результаты. Добавление кортикостероидов на ранних сроках лечения бактериальных язв роговицы способствует ингибированию воспаления, снижению активности коллагенолизиса, сокращению размера язвенного дефекта и подавлению ангиогенеза, что приводит к изменению качества рубцовой ткани.</p></sec><sec><title>Заключение</title><p>Заключение. Добавление к схеме лечения кортикостероидов местно в виде парабульбарных инъекций способствует изменению качества формирующейся фиброзной ткани, заполняющей язвенный дефект: образуется тонкий рубец, более выгодный в оптическом отношении.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to conduct a clinical and morphological study of the role of corticosteroids in the healing of the ulcerative defect on an experimental model of the bacterial corneal ulcer.</p></sec><sec><title>Material  and methods</title><p>Material  and methods. The developed model of the bacterial corneal ulcer was used. Rabbits with bacterial corneal ulcer were divided into 4 groups of 10 animals (10 eyes) each. Group 1 received local antibacterial treatment. Groups 2 and 3 additionally  received injections of 0.2–0.3 ml of Dexamethasone 0.1 % solution once per day (parabulbarly  or under the skin of the back,  respectively). Group 4 received no treatment but was checked  clinically after ulcer modeling. Structural changes in eye tissues were assessed by histopathological examination  using an examination  on a Leica microscope system with a magnification of 100 to 600.</p></sec><sec><title>Results</title><p>Results. Addition of corticosteroids in the early period of bacteria ulcer treatment contributes to an inhibition of the inflammatory process, reduces the action of collagenolysis processes and the size of the ulcer defect, and suppresses angiogenesis, which leads to an improvement in scar tissue quality.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>бактериальные язвы роговицы</kwd><kwd>кортикостероидная терапия</kwd><kwd>эксперимент</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bacterial corneal ulcers</kwd><kwd>corticosteroid therapy</kwd><kwd>experiment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tuli S.S., Schultz G.S., Downer D.M. Science and strategy for preventing and managing corneal ulceration. Ocul. Surf. 2007; 5: 23–39. doi: 10.1016/s1542-0124(12)70050-2</mixed-citation><mixed-citation xml:lang="en">Tuli S.S., Schultz G.S., Downer D.M. Science and strategy for preventing and managing corneal ulceration. Ocul. Surf. 2007; 5: 23–39. doi: 10.1016/s1542-0124(12)70050-2</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Evans D.J., Fleiszig S.M.J. Why does the healthy cornea resist Pseudomonas aeruginosa infection Am. J. Ophthalmol. 2013; 155 (6): 961–70. doi:10.1016/j.ajo.2013.03.00</mixed-citation><mixed-citation xml:lang="en">Evans D.J., Fleiszig S.M.J. Why does the healthy cornea resist Pseudomonas aeruginosa infection Am. J. Ophthalmol. 2013; 155 (6): 961–70. doi:10.1016/j.ajo.2013.03.00</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Каспарова Евг. А. Гнойные язвы роговицы: этиология, патогенез, классификация. Вестник офтальмологии. 2015; 131 (5): 87–97. doi: 10.17116/oftalma2015131587-97</mixed-citation><mixed-citation xml:lang="en">Kasparova Evg.A. Purulent corneal ulcers: etiology, pathogenesis, classification. Vestnik oftal'mologii. 2015; 131 (5): 87–97 ( in Russian). doi: 10.17116/oftalma2015131587-97</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L., Hazlett L.D. Human corneal epithelial extracellular matrix perlecan serves as a site for Pseudomonas aeruginosa binding. Curr. Eye Res. 2001; 22 (1): 19–27. doi:10.1076/ceyr.22.1.19.6973</mixed-citation><mixed-citation xml:lang="en">Chen L., Hazlett L.D. Human corneal epithelial extracellular matrix perlecan serves as a site for Pseudomonas aeruginosa binding. Curr. Eye Res. 2001; 22 (1): 19–27. doi:10.1076/ceyr.22.1.19.6973</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Marquart M.E., O’Callaghan R.J. Infectious keratitis: secreted bacterial proteins that mediate corneal damage. J. Ophthalmol. 2013; 2013:369094. doi:10.1155/2013/369094</mixed-citation><mixed-citation xml:lang="en">Marquart M.E., O’Callaghan R.J. Infectious keratitis: secreted bacterial proteins that mediate corneal damage. J. Ophthalmol. 2013; 2013:369094. doi:10.1155/2013/369094</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Осташевский В.Л., Горгиладзе Т.У. Лечебное действие инстилляций контрикала при гнойном язвенном кератите. Офтальмологический журнал. 1984; 6: 350–3.</mixed-citation><mixed-citation xml:lang="en">Ostashevsky V.L., Gorgiladze T.U. The therapeutic effect of contrykal instillations in purulent ulcerative keratitis. Ophthalmological journal (Ukraine). 1984; 6: 350–3 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bukowiecki A., Hos D., Cursiefen C., Eming S.A. Wound-healing studies in cornea and skin: parallels, differences and opportunities. Int. J. Mol. Sci. 2017 Jun; 18 (6): 1257. doi: 10.3390/ijms18061257</mixed-citation><mixed-citation xml:lang="en">Bukowiecki A., Hos D., Cursiefen C., Eming S.A. Wound-healing studies in cornea and skin: parallels, differences and opportunities. Int. J. Mol. Sci. 2017 Jun; 18 (6): 1257. doi: 10.3390/ijms18061257</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fleiszig S.M., Evans D.J. The pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosa. Clin. Exp. Optom. 2002; 85: 271–8. doi:10.1111/j.1444-0938.2002.tb03082.x</mixed-citation><mixed-citation xml:lang="en">Fleiszig S.M., Evans D.J. The pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosa. Clin. Exp. Optom. 2002; 85: 271–8. doi:10.1111/j.1444-0938.2002.tb03082.x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tuli S.S., Schultz G.S., Downer D.M. Science and strategy for preventing and managing corneal ulceration. Ocul. Surf. 2007 Jan; 5 (1): 23–39. doi: 10.1016/s1542-0124(12)70050-2</mixed-citation><mixed-citation xml:lang="en">Tuli S.S., Schultz G.S., Downer D.M. Science and strategy for preventing and managing corneal ulceration. Ocul. Surf. 2007 Jan; 5 (1): 23–39. doi: 10.1016/s1542-0124(12)70050-2</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chang J.H., Garg N., Lunde E., et al. Corneal neovascularization: an antiVEGF therapy review. Surv. Ophthalmol., 2012; 57: 415–29. doi: 10.1016/j. survophthal.2012.01.007</mixed-citation><mixed-citation xml:lang="en">Chang J.H., Garg N., Lunde E., et al. Corneal neovascularization: an antiVEGF therapy review. Surv. Ophthalmol., 2012; 57: 415–29. doi: 10.1016/j. survophthal.2012.01.007</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chang J.H., Gabison E.E., Kato T., Aza D.T. Corneal neovascularization. Curr. Opin. Ophthalmol. 2001; 12: 242–9. doi:10.1097/00055735-200108000-00002</mixed-citation><mixed-citation xml:lang="en">Chang J.H., Gabison E.E., Kato T., Aza D.T. Corneal neovascularization. Curr. Opin. Ophthalmol. 2001; 12: 242–9. doi:10.1097/00055735-200108000-00002</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shaik-Dasthagirisaheb Y.B., Varvara G., Murmura G., et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int. J. Immunopathol. Pharmacol. 2015; 26: 327–35. doi: 10.1177/039463201302600206</mixed-citation><mixed-citation xml:lang="en">Shaik-Dasthagirisaheb Y.B., Varvara G., Murmura G., et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int. J. Immunopathol. Pharmacol. 2015; 26: 327–35. doi: 10.1177/039463201302600206</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Srinivasan M., Lalitha P., Mahalakshmi R. Corticosteroids for bacterial corneal ulcers. Br. J. Ophthalmol. 2009; 93 (2): 198–202. doi: 10.1136/bjo.2008.147298</mixed-citation><mixed-citation xml:lang="en">Srinivasan M., Lalitha P., Mahalakshmi R. Corticosteroids for bacterial corneal ulcers. Br. J. Ophthalmol. 2009; 93 (2): 198–202. doi: 10.1136/bjo.2008.147298</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hindman H.B., Patel S.B., Jun A.S. Rationale for adjunctive topical corticosteroids in bacterial keratitis. Arch. Ophthalmol. 2009; 127 (1): 97–102. doi: 10.1001/archophthalmol.2008.504</mixed-citation><mixed-citation xml:lang="en">Hindman H.B., Patel S.B., Jun A.S. Rationale for adjunctive topical corticosteroids in bacterial keratitis. Arch. Ophthalmol. 2009; 127 (1): 97–102. doi: 10.1001/archophthalmol.2008.504</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ohadi C., Litwin K.L., Moreira H. Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis. Cornea. 1992; 11 (5): 398–403.</mixed-citation><mixed-citation xml:lang="en">Ohadi C., Litwin K.L., Moreira H. Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis. Cornea. 1992; 11 (5): 398–403.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Badenoch P.R., Hay G.J., McDonald P.J., Coster D.J. A rat model of bacterial keratitis: effect of antibiotics and corticosteroid. Arch. Ophthalmol. 1985; 103 (5): 718–22.</mixed-citation><mixed-citation xml:lang="en">Badenoch P.R., Hay G.J., McDonald P.J., Coster D.J. A rat model of bacterial keratitis: effect of antibiotics and corticosteroid. Arch. Ophthalmol. 1985; 103 (5): 718–22.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fel A., Aslangul E., Le Jeunne C. Eye and corticosteroid's use. Presse Med. 2012; 41: 414–21. doi: 10.1016/j.lpm.2012.02.001</mixed-citation><mixed-citation xml:lang="en">Fel A., Aslangul E., Le Jeunne C. Eye and corticosteroid's use. Presse Med. 2012; 41: 414–21. doi: 10.1016/j.lpm.2012.02.001</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Shakiba Y., Mansouri K., Arshadi D., Rezaei N. Corneal neovascularization: molecular events and therapeutic options. Recent Pat. Inflamm. Allergy Drug. Discov. 2009; 3: 221–31. doi:10.2174/187221309789257450</mixed-citation><mixed-citation xml:lang="en">Shakiba Y., Mansouri K., Arshadi D., Rezaei N. Corneal neovascularization: molecular events and therapeutic options. Recent Pat. Inflamm. Allergy Drug. Discov. 2009; 3: 221–31. doi:10.2174/187221309789257450</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hos D., Saban D.R., Bock F., et al. Suppression of inflammatory corneal lymphagniogenesis by application of topical corticosteroids. Arch. Ophthalmol. 2011. 129: 445–52. doi:0.1001/archophthalmol.2011.42</mixed-citation><mixed-citation xml:lang="en">Hos D., Saban D.R., Bock F., et al. Suppression of inflammatory corneal lymphagniogenesis by application of topical corticosteroids. Arch. Ophthalmol. 2011. 129: 445–52. doi:0.1001/archophthalmol.2011.42</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tuli S.S. Topical corticosteroids in the management of bacterial keratitis. Curr. Ophthalmol. Rep. 2013 Dec; 1 (4). doi:10.1007/s40135-013-0026-0</mixed-citation><mixed-citation xml:lang="en">Tuli S.S. Topical corticosteroids in the management of bacterial keratitis. Curr. Ophthalmol. Rep. 2013 Dec; 1 (4). doi:10.1007/s40135-013-0026-0</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Den S., Sotozono C., Kinoshita S., Ikeda T. Efficacy of early systemic betamethasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction. Acta Ophthalmol. Scand. 2004; 82: 195–9. doi: 10.1111/j.1600-0420.2004.00229.x</mixed-citation><mixed-citation xml:lang="en">Den S., Sotozono C., Kinoshita S., Ikeda T. Efficacy of early systemic betamethasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction. Acta Ophthalmol. Scand. 2004; 82: 195–9. doi: 10.1111/j.1600-0420.2004.00229.x</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yi K., Chung T.Y., Hyon J.Y., et al. Combined treatment with antioxidants and immunosuppressants on cytokine release by human peripheral blood mononuclear cells — chemically injured keratocyte reaction. Mol. Vis. 2011; 17: 2665–71. PMID:22065919</mixed-citation><mixed-citation xml:lang="en">Yi K., Chung T.Y., Hyon J.Y., et al. Combined treatment with antioxidants and immunosuppressants on cytokine release by human peripheral blood mononuclear cells — chemically injured keratocyte reaction. Mol. Vis. 2011; 17: 2665–71. PMID:22065919</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Srinivasan M., Mascarenhas J., Rajaraman R. Steroids for corneal ulcers trial group. corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch. Ophthalmol. 2012; 130 (2): 143–50. doi: 10.1001/ archophthalmol.2011.315</mixed-citation><mixed-citation xml:lang="en">Srinivasan M., Mascarenhas J., Rajaraman R. Steroids for corneal ulcers trial group. corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch. Ophthalmol. 2012; 130 (2): 143–50. doi: 10.1001/archophthalmol.2011.315</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Бикбов М.М., Никитин Н.А., Суркова В.К., Зайнуллина Н.Б. Способ моделирования бактериального кератита. Патент РФ 2480845.</mixed-citation><mixed-citation xml:lang="en">Bikbov M.M., Nikitin N.A., Surkova V.K., Zaynullina N.B. Method of modeling bacterial keratitis. Patent RU, N2480845 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Панова И.Г., Маркитантова Ю.В., Смирнова Ю.А., Зиновьева Р.Д. Молекулярно-генетические механизмы морфогенеза роговицы. Известия РАН. Серия биологическая. 2015; 42 (2): 117–26. doi: 10.7868/s0002332915020071</mixed-citation><mixed-citation xml:lang="en">Panova I.G., Markitantova Y.V., Smirnova Y.A., Zinovieva R.D. Moleculargenetic mechanisms of cornea morphogenesis. Biology Bulletin. 2015; 42 (2): 83–91. doi: 10.7868/s0002332915020071</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Симирский В.Н. Регенерация и фиброз тканей роговицы. Онтогенез. 2014; 45 (5): 314–25. doi: 10.7868/s0475145014050097</mixed-citation><mixed-citation xml:lang="en">Simirskii V.N. Regeneration and fibrosis of corneal tissues. Ontogenes. 2014; 45 (5): 314–25 (in Russian). doi:10.7868/s0475145014050097</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hassell J.R., Birk D.E. The molecular basis of corneal transparency. Exp. Eye Res. 2010; 91 (3): 326–35. doi:10.1016/j.exer.2010.06.021</mixed-citation><mixed-citation xml:lang="en">Hassell J.R., Birk D.E. The molecular basis of corneal transparency. Exp. Eye Res. 2010; 91 (3): 326–35. doi:10.1016/j.exer.2010.06.021</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В.В., Яни Е.В., Голикова В.А., Позднякова В.В. Оценка схем консервативного лечения бактериальных язв роговицы с применением глюкокортикостероидного препарата в эксперименте. Российский офтальмологический журнал. 2020;13 (2): 71–7. https://doi.org/10.21516/2072-0076-2020-13-2-71-77</mixed-citation><mixed-citation xml:lang="en">Neroev V.V., Yani E.V., Golikova V.A., Pozdnyakova V.V. Experimental evaluation of bacterial corneal ulcer treatment plans using glucocorticosteroid. Russian ophthalmological journal. 2020; 13 (2): 71–7 (In Russian). https://doi.org/10.21516/2072-0076-2020-13-2-71-77</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
